Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Investigator-Initiated Study to Be Launched for Telomelysin/Radiotherapy in US: Oncolys
Oncolys BioPharma said on June 10 that it has entered into an agreement with NRG Oncology, a US non-profit research organization, in order to commence a PI investigator-initiated trial (IIT) of the Japanese company’s oncolytic viral immunotherapy telomelysin (OBP-301) in…
To read the full story
Related Article
- Oncolys Aims for First-Line Use of Telomelysin in Esophageal Cancer
January 19, 2026
- Oncolys Files Telomelysin in Japan, Eyes API Manufacturing Expansion in Asia
December 16, 2025
- Oncolys Seeks Marketing License for Regenerative Medicine in Japan
November 27, 2024
- Oncolys Forms Oncolytic Virus Sales Collab with Fujifilm in Japan
February 8, 2024
- Telomelysin-Radiation Combo Hits Mark in PII Esophageal Cancer Study: Oncolys
October 17, 2023
- Oncolys Keeps 2024 Target for Japan Telomelysin Filing; Partner Talks Ongoing
December 20, 2022
- PI Telomelysin Trial for Esophageal Cancer Begins in US: Oncolys
December 8, 2021
- Telomelysin-Keytruda Combo Trial to Begin in US for Head and Neck Cancer: Oncolys
August 11, 2020
- US PII Study for Telomelysin-Keytruda Combo Begins for Esophageal Cancer
May 14, 2019
- Investigator-Initiated US PII Study to Start for Telomelysin/Keytruda Combo: Oncolys
January 9, 2019
BUSINESS
- J&J’s Tremfya Now Available for Self-Injection in IBD
June 2, 2026
- J&J Taps Leading Cancer Centers to Bolster Japan Trial Environment
June 2, 2026
- BMS Files Breyanzi for Relapsed/Refractory CLL, SLL in Japan
June 1, 2026
- Astellas Rebuts ISS Opposition to Outside Director Nominee
June 1, 2026
- Meiji Backs US Fund Supporting Pandemic Preparedness
June 1, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…